Marcus Lefebure

1.1k total citations
14 papers, 288 citations indexed

About

Marcus Lefebure is a scholar working on Genetics, Pathology and Forensic Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Marcus Lefebure has authored 14 papers receiving a total of 288 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 7 papers in Pathology and Forensic Medicine and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Marcus Lefebure's work include Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Marcus Lefebure is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Marcus Lefebure collaborates with scholars based in United States, Australia and United Kingdom. Marcus Lefebure's co-authors include Jake Shortt, Ricky W. Johnstone, P. Leif Bergsagel, Marta Chesi, Geoffrey M. Matthews, Stephen Palmer, Victoria M. Garbitt, A. Keith Stewart, Eva Vidacs and Richard W. Tothill and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Marcus Lefebure

12 papers receiving 287 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marcus Lefebure United States 6 179 152 88 56 56 14 288
Monica Testoni Switzerland 4 230 1.3× 120 0.8× 92 1.0× 36 0.6× 33 0.6× 7 321
Ashley F. Ward United States 5 146 0.8× 139 0.9× 72 0.8× 112 2.0× 36 0.6× 6 290
Céline Bellanger France 9 157 0.9× 70 0.5× 120 1.4× 88 1.6× 86 1.5× 21 318
Swathi-Rao Narayanagari United States 4 194 1.1× 200 1.3× 58 0.7× 61 1.1× 90 1.6× 4 374
Erin Flynt United States 9 341 1.9× 312 2.1× 154 1.8× 30 0.5× 39 0.7× 28 429
Vladimir Vorobyev Russia 10 185 1.0× 228 1.5× 137 1.6× 85 1.5× 27 0.5× 39 383
Ruth Schwab Germany 4 163 0.9× 300 2.0× 103 1.2× 132 2.4× 39 0.7× 4 380
Valentina Agnusdei Italy 10 205 1.1× 69 0.5× 65 0.7× 21 0.4× 39 0.7× 11 316
Dejan Radeski Australia 9 164 0.9× 35 0.2× 140 1.6× 34 0.6× 45 0.8× 20 307
Amanda d’Almeida United States 2 181 1.0× 194 1.3× 56 0.6× 52 0.9× 60 1.1× 2 304

Countries citing papers authored by Marcus Lefebure

Since Specialization
Citations

This map shows the geographic impact of Marcus Lefebure's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcus Lefebure with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcus Lefebure more than expected).

Fields of papers citing papers by Marcus Lefebure

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marcus Lefebure. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcus Lefebure. The network helps show where Marcus Lefebure may publish in the future.

Co-authorship network of co-authors of Marcus Lefebure

This figure shows the co-authorship network connecting the top 25 collaborators of Marcus Lefebure. A scholar is included among the top collaborators of Marcus Lefebure based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcus Lefebure. Marcus Lefebure is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Shadman, Mazyar, Talha Munir, Shuo Ma, et al.. (2025). Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/ TP53 Mutation: SEQUOIA Arm D Results. Journal of Clinical Oncology. 43(21). 2409–2417. 3 indexed citations
2.
Shadman, Mazyar, Constantine S. Tam, Danielle M. Brander, et al.. (2025). CLL-769: Efficacy and Safety of Zanubrutinib in a Fit Subgroup of Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL): Post Hoc Analyses From the SEQUOIA Study. Clinical Lymphoma Myeloma & Leukemia. 25. S531–S531.
3.
Kater, Arnon P., Barbara Eichhorst, Carolyn Owen, et al.. (2024). Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab. HemaSphere. 8(8). e146–e146. 1 indexed citations
4.
5.
Kater, Arnon P., Rosemary Harrup, Thomas J. Kipps, et al.. (2023). MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Hematological Oncology. 41(S2). 239–242. 8 indexed citations
6.
Barrett, Kathy, et al.. (2023). Abstract 1869: Preclinical evaluation of mosunetuzumab for the treatment of relapsed/refractory chronic lymphocytic leukemia. Cancer Research. 83(7_Supplement). 1869–1869. 1 indexed citations
7.
Kater, Arnon P., Rosemary Harrup, Thomas J. Kipps, et al.. (2023). S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL). HemaSphere. 7(S3). e492813f–e492813f. 11 indexed citations
8.
Kater, Arnon P., Barbara Eichhorst, Carolyn Owen, et al.. (2022). Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 140(Supplement 1). 7010–7012. 1 indexed citations
9.
Wu, Jane, John F. Seymour, Barbara Eichhorst, et al.. (2021). UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY. Hematological Oncology. 39(S2). 2 indexed citations
10.
11.
12.
Hogg, Simon J., Andrea Newbold, Stephin J. Vervoort, et al.. (2016). BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Molecular Cancer Therapeutics. 15(9). 2030–2041. 50 indexed citations
13.
Matthews, Geoffrey M., Marcus Lefebure, Maria Doyle, et al.. (2013). Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. Cell Death and Disease. 4(9). e798–e798. 41 indexed citations
14.
Chesi, Marta, Geoffrey M. Matthews, Victoria M. Garbitt, et al.. (2012). Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood. 120(2). 376–385. 152 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Monica Testoni Breakdown of academic impact, for papers by Ashley F. Ward Breakdown of academic impact, for papers by Céline Bellanger Breakdown of academic impact, for papers by Swathi-Rao Narayanagari Breakdown of academic impact, for papers by Erin Flynt Breakdown of academic impact, for papers by Vladimir Vorobyev Breakdown of academic impact, for papers by Ruth Schwab Breakdown of academic impact, for papers by Valentina Agnusdei Breakdown of academic impact, for papers by Dejan Radeski Breakdown of academic impact, for papers by Amanda d’Almeida
Rankless by CCL
2026